Breaking News: SOL-1 Superiority Data for Axpaxli in Wet AMD

Hosts:John Kitchens, MDScott KrzywonosShow Summary:In this emergency episode of RetinUp, John and Scott break down the newly announced SOL-1 study data evaluating Axpaxli (Ocular Therapeutix) for the treatment of wet AMD.The superiority trial compared a single Axpaxli injection to a single Eylea injection (after all eyes received a pair of monthly Eylea doses) in patients with wet AMD. The primary endpoint was the proportion of patients maintaining vision at 36 weeks (defined as losing fewer than 15 ETDRS letters).Key findings include:74% of Axpaxli patients maintained vision at 36 weeks vs. 59% in the Eylea armApproximately 75% of Axpaxli patients required no rescue treatment through 36 weeksDurable disease control extending 24–36 weeks, with some patients reaching 52 weeksJohn and Scott discuss:How the SOL-1 study design (FDA-aligned superiority endpoint) shaped the resultsWhat this means for durability beyond traditional anti-VEGF therapiesWhy the market reaction diverged from clinical enthusiasmHow to talk to your patients who hear about study dataWhat to expect next from the SOL-R study and a potential FDA submissionWhy It Matters:For the first time in years, retina specialists may be looking at a new mechanism of action — a tyrosine kinase inhibitor — with the potential to significantly extend treatment intervals after a single injection.More detailed analysis and expert commentary coming soon on RetinUp.Listen & Subscribe:RetinUp.com | Apple Podcasts | Spotify | YouTubeCredits:Production & Marketing: Laura BrownBusiness Operations: Liz Hogan